^
Association details:
| Biomarker: | RPL22L1 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma
Published date:
08/17/2022
Excerpt:
We further tested the effect of RPL22L1 on sorafenib sensitivity of HCC cells. RPL22L1 overexpression resulted in a poor response to sorafenib, as illustrated by an increased half-inhibitory concentration (IC50) and clonogenic growth...
DOI:
https://doi.org/10.1038/s41420-022-01153-8
